Tricida, Inc. Securities Litigation

If you purchased a significant amount of shares of Tricida, Inc. (NASDAQ: TCDA), you have certain options. Investors should contact us.


Lawsuit Overview

Defendant:Tricida, Inc.
Date Filed:January 6th, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:September 4th, 2019
Class End Date:October 28th, 2020

According to the Complaint, Tricida, Inc. is a pharmaceutical company that focuses on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease ("CKD"). Tricida has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company's business, operational, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and failed to disclose to investors that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Tricida, Inc.

First Identified Complaint

Michael Pardi, et al. v. Tricida, Inc., et al.

Date Filed:January 6th, 2021
Class Period Start:September 4th, 2019
Class Period End:October 28th, 2020
First Identified Complaint Filings
#Document TitleFiling Date